Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InnoCan Pharma ( (TSE:INNO) ) has provided an announcement.
Innocan Pharma announced promising preliminary findings regarding its liposomal cannabidiol (LPT-CBD) technology. Results from tests conducted on Göttingen minipigs demonstrated sustained CBD release in plasma for 28 days after a single subcutaneous injection, with comparable CBD metabolism to human systems and an excellent safety profile. This advancement strengthens its alignment with FDA non-clinical development plans and signifies a noteworthy step toward translating the technology into human applications, reaffirming the company’s leadership in biotechnology and pharmaceutical innovation.
The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$10.50 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.
Spark’s Take on TSE:INNO Stock
According to Spark, TipRanks’ AI Analyst, TSE:INNO is a Neutral.
InnoCan Pharma’s overall stock score is driven by its financial challenges and bearish technical indicators, which are partially offset by positive corporate events related to its LPT-CBD technology. The company’s negative valuation metrics further weigh on the score, highlighting the need for improved financial performance and market sentiment.
To see Spark’s full report on TSE:INNO stock, click here.
More about InnoCan Pharma
Innocan Pharma is a leader in the pharmaceutical and wellness sectors, specializing in innovative drug delivery systems and self-care products. The company is known for its development of a CBD-loaded liposome drug delivery platform aimed at providing non-opioid pain management, and also offers a range of wellness and beauty products through its subsidiary BI Sky Global Ltd.
Average Trading Volume: 1,847
Technical Sentiment Signal: Sell
Current Market Cap: C$33.74M
For detailed information about INNO stock, go to TipRanks’ Stock Analysis page.